Compare Crispr Therapeutics AG (CRSP) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fiverr International Ltd — how do they compare? Crispr Therapeutics AG trades at $51.34 (market cap $4.97B), while Fiverr International Ltd trades at $11.28 (market cap $397.97M). The key difference: Crispr Therapeutics AG is far larger — about 12.5× Fiverr International Ltd's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| CRSP | FVRR | |
|---|---|---|
Market Cap | $4.97B | $397.97M |
Sector | Health | Industrials |
52-Week High | $76.78 | $26.67 |
52-Week Low | $44.34 | $9.62 |
Enterprise Value | $3.32B | $128.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Fiverr International (FVRR) trades at $11.27, up 2.08% today, with a bullish technical signal from moving averages. Revenue grew to $430.91M in 2025, with net income reaching $20.98M and a 4.86% margin. The stock appears undervalued with a P/E of 14.64 and P/S of 0.97. Recent news highlights Fiverr's upcoming Q2 2026 earnings and a surge in demand for AI coding specialists, though the stock remains near its 52-week low, down 66% from its high.
The outlook is mixed: strong profitability metrics and low valuation ratios present a potential opportunity, but risks include declining active buyers, ongoing legal investigations, and volatile cash flows. Analyst consensus leans neutral with 41% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
